Study Evaluating the Effect of IMA-638 in Subjects With Persistent Asthma

Summary

Primary purpose is to assess if IMA-638 is safe and improves asthma in subjects with persistent asthma.

Timeline

Start

2007-02

Primary completion

2008-08

Completion

2008-08

Outcome

Missed primary endpoint

registry IMA-638 200 mg: Stage 2 and 3 vs Placebo: Stage 2 and 3; p = 0.612; Least squares (LS) mean difference -5.2 (95% CI -25.6 to 15.2); ANCOVA NCT00425061 ↗

Drugs

Indications